RxDoctor Payments Data

Alla Grigorian, MD

Gastroenterology · Lexington, KYNPI 1275551244

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,440 of the $9,590 with a category attached, or 88.0%. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 83.4% of it on its own, with 3 other manufacturers making up the rest. 2023 is the largest year on record at $8,000, 7.8 times the $1,028 reported in 2020.

$9,590in general payments, 2019–2025

Across 14 payments — averaging $685.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$8K
  • Olympus Corporation Of The Americas$1K
  • Intercept Pharmaceuticals, Inc.$440
  • AbbVie$123
$184,777in research payments, 2019–2025

Across 79 payments — averaging $2338.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Intercept Pharmaceuticals, Inc.$157K
  • Intercept Pharma Europe Ltd.$27K

What the payments were for

  • Speaking & faculty fees$8,44088%
  • Travel & lodging$1,00811%
  • Food & beverage$1421%

General payments by program year

20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,590 in reported general payments places this provider in the 80th percentile of 207 gastroenterology providers in Kentucky.

See all gastroenterology providers in Kentucky

Medicare billing

Part B allowed, 2024
$29,450
Medicare patients
145
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin68$210,588
TrulancePlecanatide12$6,500
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl20$331
Spironolactone19$177
Omeprazole15$58
Furosemide16$50
Carvedilol15$10

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$8,000$217,08880 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 207 gastroenterology providers in Kentucky.

Other gastroenterology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →